Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Essential Amino Acids in Parkinson's Disease
NCT06604065Phase 1Withdrawn
- Sponsor
- University of Arkansas
- Start
- Mar 2026
- Primary completion
- Mar 2026
- Modality
- Small Molecules
01
Overview
Phase 1 trial of AMS2434 in Parkinson's disease (PD) (2 arms), sponsored by University of Arkansas. Primary endpoint: Muscle Protein Synthesis at 4 hours. Planned start Mar 2026; status: withdrawn.
02
Drugs
AMS2434
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06604065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06604065.